Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Progesterone Resistance 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Cyproterone acetate, ethinyl estradiol drug combination × Gynecologic × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡